Search results
Results from the WOW.Com Content Network
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
Glipizide, sold under the brand name Glucotrol among others, is an anti-diabetic medication of the sulfonylurea class used to treat type 2 diabetes. [1] [2] It is used together with a diabetic diet and exercise. [1] [2] It is not indicated for use by itself in type 1 diabetes. [1] [2] It is taken by mouth.
Orlistat (Xenical), the most commonly used medication to treat obesity and sibutramine (Meridia), a medication that was withdrawn due to cardiovascular side effects. Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control excess body fat.
However, he says you can often lower your risk of side effects by staying well hydrated, eating smaller meals, and limiting processed foods, high-fat foods, and refined carbohydrates.
People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than those other diabetes drugs. ... at the Division of Pharmacoepidemiology at ...
How hunger hormones control growth. When you go too long without eating, your body enters a fasted state. During this time, your stomach releases a hormone called ghrelin, which signals your brain ...
In the US semaglutide (Wegovy) is indicated, in combination with a reduced calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and who are either obese or overweight ...
The study consisted of 48 participants (34 women, 14 men), with half the participants receiving a weekly low-dose injection of semaglutide, while the other half received a placebo.